In clinical studies, AUSTEDO® reduced tardive dyskinesia symptoms while people continued on their mental health medications.1-3

AUSTEDO® reduced the involuntary, repetitive, uncontrolled movements of TD in 2 clinical studies.

Study 1: Involuntary movement reduction at week 121

Study 1: Involuntary movement reduction at week 121

%
TAKING AUSTEDO®
vs
%
TAKING PLACEBO
AUSTEDO® (deutetrabenazine) tablets Clinical Study Reduced AIMS* Score Created with Sketch. placebo AUSTEDO ®
  • AUSTEDO® reduced the AIMS total score by
    3.3 points vs 1.4 points with placebo from the start of the study.
  • For participants taking AUSTEDO®, this represents a 33% reduction in AIMS total score vs a 12% reduction for those taking placebo.
  • Improvement in uncontrolled movements began to be seen at 2 weeks.

A reduction in AIMS total score means reduced involuntary movements.1,4

understanding aims

Study 2: Involuntary movement reduction at week 121

Study 2: Involuntary movement reduction at week 121

%
TAKING AUSTEDO®
vs
%
TAKING PLACEBO
AUSTEDO® (deutetrabenazine) tablets Clinical Study Created with Sketch. placebo AUSTEDO ®
  • AUSTEDO® reduced the AIMS total score by 3.0 points vs 1.6 points with placebo.
  • This represents an approximately 27% reduction in AIMS total score for people taking AUSTEDO® vs a 16% reduction for those taking placebo.

Download the Doctor Discussion Guide

Use this resource at your next appointment—whether it’s in person or through telemedicine—to help you and your doctor decide if AUSTEDO® is right for you.

You are about to leave this site

You are about to leave AUSTEDO.com and enter a website operated by a third party. Teva is not responsible for and does not control the content contained on this third-party website linked to AUSTEDO.com.

Are you a healthcare professional?

The information on this site is intended for healthcare professionals in the United States. Are you a healthcare professional in the United States?

References: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Teva Pharmaceuticals USA, Inc. 2. Data on file. Teva Neuroscience, Inc. 3. Warikoo N, Schwartz T, Citrome L. Tardive dyskinesia. In: Aguilar, M, ed. Antipsychotic Drugs: Classification, Pharmacology and Long-Term Health Effects. Hauppauge, NY: Nova Science Publishers, Inc; 2013:235-258. 4. Abnormal Involuntary Movements Scale (AIMS) – overview. Center for Quality Assessment and Improvement in Mental Health website. http://www.cqaimh.org/pdf/tool_aims.pdf. Accessed September 4, 2019.